BridgeBio Pharma, Inc. Increase (Decrease) in Due from Related Parties
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Due from Related Parties of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedParties · last filed 2023-02-23
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for the quarter ending 2021-12-31 was -$462.00K.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for the quarter ending 2021-09-30 was -$8.50M.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for the quarter ending 2021-06-30 was $8.50M.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for the quarter ending 2021-03-31 was $462.00K.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for fiscal 2022 was $0.00.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for fiscal 2021 was $0.00.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for fiscal 2020 was -$2.85M, a 200.00% decline from fiscal 2019.
- BridgeBio Pharma, Inc. increase (decrease) in due from related parties for fiscal 2019 was $2.85M.
| Period end | Increase (Decrease) in Due from Related Parties 3 month | Increase (Decrease) in Due from Related Parties 6 month | Increase (Decrease) in Due from Related Parties 9 month | Increase (Decrease) in Due from Related Parties 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2021-12-31 | -$462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$8.96M derived: sum of 2 quarters · filed 2023-02-23 | -$462.00K derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2021-09-30 | -$8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $462.00K 10-Q · filed 2022-11-03 | -$7.54M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $8.96M 10-Q · filed 2022-08-04 | $962.00K derived: sum of 3 quarters · filed 2023-02-23 | |
| 2021-03-31 | $462.00K 10-Q · filed 2022-05-05 | -$7.54M derived: sum of 2 quarters · filed 2023-02-23 | ||
| 2020-12-31 | -$8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$2.85M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $5.16M 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | -$2.85M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $2.85M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |